Abnex has a range of projects and technologies available for licensing and commercialization.We aim to serve through new partnerships or technology transfers by leveraging our talents and assets. We have developed a number of innovative technologies and biopharmaceutical projects that subsequently are licensed to our development partners or incorporated into our portfolio companies. For example, the out licensing projects includes 4 different humanized monoclonal antibodies (1 “naked” and 3 as antibody-drug conjugates), 2 monoclonal antibodies (immune checkpoint inhibitors) for immunotherapy and an innovative platform for bispecific antibody production. When you collaborate or consult with us, you are getting much more than a high quality service. You gain access to our array of technical resources, including the scientific know-how. Our dedicated team of scientists and professionals is available to quickly address your needs as they arise. Our team has a thorough understanding of the latest tools and advances in antibody therapeutic R&D.